Archive


Category: Biosimilar Darbepotein Alfa

  • Menagen Signs a Commercialization Agreement with CKD for Biosimilar Darbepotein Alfa

    Shots: The companies collaborated to commercialize the first biosimilar Darbepoetin alpha in the GCC market for the treatment of anemia associated with chronic renal failure. The CKD biosimilar is currently approved in South Korea The collaboration with CKD helps to build the biosimilar footprint in the Middle East and Africa markets to reach more people […]